DRUG — Bright Minds Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- CA$935.30m
- CA$852.52m
- 39
- 26
- 86
- 49
Annual cashflow statement for Bright Minds Biosciences, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.65 | -15 | -7.37 | -2.8 | -12.2 |
| Depreciation | |||||
| Non-Cash Items | 0.657 | 0.648 | 1.22 | 0.839 | 2.91 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.675 | 0.724 | -0.942 | 0.04 | 0.555 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -7.32 | -13.6 | -7.02 | -1.85 | -8.69 |
| Financing Cash Flow Items | -1.79 | -0.8 | -0.027 | 0 | -0.36 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 26.1 | 5.2 | 2.19 | 0.811 | 85.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 19 | -8.13 | -4.88 | -1.03 | 77.2 |